Klaria Year-End Report
Klaria Year-End Report 1 January–31 December 2022 Q4 2022
Summary of the Year-End Report
Successful rights issue brought 59.2 MSEK to Klaria
New collaboration agreement signed with PharmaMar fourth quarter of 2022
- Net sales amounted to 2.2 MSEK (0.0 MSEK)
- Other income amounted to 0.2 MSEK (6.2 MSEK)
- R&D costs for the period amounted to 8.6 MSEK (28.1 MSEK)
- Profit after tax amounted to -12.9 MSEK (-24.8 MSEK)
- Earnings per share for the quarter amounted to -0.22 SEK (-0.48 SEK)
- Cash flow from operating activities amounted to -10.7 MSEK (-14.6 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 16.8 MSEK (25.5 MSEK)
- Equity as of December 31 amounted to 76.0 MSEK (69.4 MSEK) The period January-December 2021
- Net sales amounted to 5.9 MSEK (0.0 MSEK)
- Other income amounted to 0,7 MSEK (37.5 MSEK)
- R&D costs for the period amounted to 51.4 MSEK (63.5 MSEK)
- Profit after tax amounted to -63.8 MSEK (-53.5 MSEK)
- Earnings per share for the quarter amounted to -1.10 SEK (-1.03 SEK)
- Cash flow from operating activities amounted to -49.8 MSEK (-24.8 MSEK)
- Cash and cash equivalents in the parent company amounted to 15.5 MSEK (9.1 MSEK)
- Equity in the parent company amounted to 175.3 MSEK (158.4 MSEK)
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.